Circulating miRNA signatures: a new challenge in castration-resistant prostate cancer.

被引：0
|
作者：
Noto, Laura
Picciotto, Maria
Curro, Monica
Franchina, Tindara
Chiofalo, Giuseppe
Del Re, Cristina
Caccamo, Daniela
Ientile, Riccardo
Adamo, Vincenzo
机构：
[1] Univ Hosp Policlin, Med Oncol, Catania, Italy
[2] Univ Messina, Dept Human Pathol, Med Oncol Unit AOOR Papardo Piemonte, Messina, Italy
[3] Univ Messina, AOU Policlin G Martino, Dept Biomed Sci & Morphol & Funct Imaging, Messina, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e16100
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16100
引用
收藏
页数：1
相关论文
共 50 条
  • [1] New Therapies for Castration-Resistant Prostate Cancer.
    Longo, Dan L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (05): : 479 - 481
  • [2] Association between circulating miRNA-141 and miRNA-375 and treatment outcome in metastatic castration-resistant prostate cancer.
    Zedan, Ahmed Hussien
    Osther, Palle Jorn Sloth
    Assenholt, Jannie
    Madsen, Jonna Skov
    Hansen, Torben
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Role of chemotherapy in castration-resistant prostate cancer. Are there new approaches?
    De Santis, M.
    Bachner, M.
    UROLOGE, 2012, 51 (01): : 39 - 43
  • [4] The plasma lipidome in castration-resistant prostate cancer.
    Horvath, Lisa
    Lin, Hui-Ming
    Mahon, Kate Lynette
    Weir, Jacquelyn
    Mundra, Piyushkumar
    Spielman, Calan
    Briscoe, Karen P.
    Gurney, Howard
    Mallesara, Girish
    Marx, Gavin M.
    Stockler, Martin R.
    Parton, Robert
    Hoy, Andrew
    Daly, Roger J.
    Meikle, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer
    Rini, Brian I.
    CURRENT ONCOLOGY REPORTS, 2009, 11 (03) : 163 - 164
  • [6] Circulating tumor cells in metastatic castration-resistant prostate cancer
    Brian I. Rini
    Current Oncology Reports, 2009, 11 : 163 - 164
  • [7] Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
    Kantoff, Philip W.
    Higano, Celestia S.
    Shore, Neal D.
    Berger, E. Roy
    Small, Eric J.
    Penson, David F.
    Redfern, Charles H.
    Ferrari, Anna C.
    Dreicer, Robert
    Sims, Robert B.
    Xu, Yi
    Frohlich, Mark W.
    Schellhammer, Paul F.
    Ahmed, T.
    Amin, A.
    Arseneau, J.
    Barth, N.
    Bernstein, G.
    Bracken, B.
    Burch, P.
    Caggiano, V.
    Chin, J.
    Chodak, G.
    Chu, F.
    Corman, J.
    Curti, B.
    Dawson, N.
    Deeken, J. F.
    Dubernet, T.
    Fishman, M.
    Flanigan, R.
    Gailani, F.
    Garbo, L.
    Gardner, T.
    Gelmann, E.
    George, D.
    Godfrey, T.
    Gomella, L.
    Guerra, M.
    Hall, S.
    Hanson, J.
    Israeli, R.
    Jancis, E.
    Jewett, M. A. S.
    Kassabian, V.
    Katz, J.
    Klotz, L.
    Koeneman, K.
    Koh, H.
    Kratzke, R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (05): : 411 - 422
  • [8] Sequential active chemotherapy schema in castration-resistant prostate cancer.
    Tang, R.
    Groshen, S. G.
    Piatek, C. I.
    Desai, B. B.
    Pinski, J. K.
    Acosta, F.
    Raghavan, D.
    Dorff, T. B.
    Quinn, D. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] A CONSENSUS DEFINITION FOR CASTRATION-RESISTANT PROSTATE CANCER. "DELPHI STUDY"
    Gomez Veiga, Francisco
    Alcaraz, A.
    Bellmunt, J.
    Rodriguez, A.
    Solsona, E.
    JOURNAL OF UROLOGY, 2011, 185 (04): : E259 - E260
  • [10] Satraplatin in Second-line of Castration-resistant Prostate cancer.
    Heidenreich, A.
    ONKOLOGE, 2010, 16 (03): : 314 - 315
12345